Pharmaceuticals Market Research Reports & Industry Analysis
Pharmaceuticals Industry Research & Market Reports
-
Global In-vitro Fertilization Market Forecast 2018-2026
... chiefly driven by growing infertility rates across the globe. Factors like improved surrogacy laws and high success rate of IVF treatments are further boosting the market expansion. MARKET INSIGHTS Products, procedures, and end-users are the ... Read More
-
2018 Testosterone Test Volume and Sales Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations
... as well as test volume and sales forecasts by country and market segment. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA Market Segmentation Centralized Testing - Hospitals Commercial/Private Laboratories POC/Decentralized Testing - Physician Offices/Group ... Read More
-
2018 US Hematology and Flow Cytometry Analyzers and Reagents: Supplier Sales and Shares, Sales Segment Forecasts - Hospitals, Commercial Laboratories, POC Locations - Competitive Landscape, Emerging Technologies, Instrumentation Review
... 306 pages, 59 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in US hematology and flow cytometry hospital, commercial and point-of-care/POC markets during the next ... Read More
-
Asia Pacific In-vitro Fertilization Market Forecast 2018-2026
... much promise for the overall global IVF market, increasing its revenue from $xx million in 2017 to $xx million by the end of 2026. MARKET INSIGHTS The cost of IVF procedures is quite cheap in ... Read More
-
North America In-vitro Fertilization Market Forecast 2018-2026
... IVF techniques include, cryobanks, hospitals and research laboratories, fertility and surgical centers. MARKET INSIGHTS Canada and United States are the primary markets in this region. The United States captured a major share of the North ... Read More
-
Europe Glucose Monitoring System Market Forecast 2018-2026
... of 33.40% over the forecast period of 2018-2026. And, the Europe Self-Monitoring of Blood Glucose (SMBG) market is expected to rise from $3005.1 million in 2017 to $5873.9 million by 2026, at a CAGR of ... Read More
-
ANI Pharmaceuticals Inc (ANIP) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Infinity Pharmaceuticals Inc (INFI) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Juniper Pharmaceuticals Inc (JNP) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Amryt Pharma plc (AMYT) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Avisa Pharma Inc - Product Pipeline Analysis, 2018 Update
... designed to detect respiratory bacterial infections in the lung and other metabolic diseases; and avisar spec, a point-of-care instrument that is used for measuring exhaled carbondioxide. Its AV-U13 drug for inhalation and nebulizer are packaged ... Read More
-
Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review
... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More
-
TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review
... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More
-
Belarus Pharmaceuticals & Healthcare Q3 2018
... receive a boost, both through foreign directinvestment and government support, high-value patented medicines will still need to be imported, given the lack of domesticcapabilities to produce them, thus, continuing to offer commercial opportunities. On the ... Read More
-
Honduras Pharmaceuticals & Healthcare Q3 2018
... counterfeit medicines and institutional corruption, with inadequateregulatory enforcement. However, a growing burden of chronic diseases driven by ageing demographics in addition to plannedhealthcare reforms will improve multinational pharmaceutical firms’ appetite for investment in Honduras, providing ... Read More
-
Pakistan Pharmaceuticals & Healthcare Q3 2018
... population suggests strong development potential,the prevalent climate of counterfeit medicines and the lacking regulatory and the general intellectual property environment makethe market an unattractive prospect. This, along with endemic political instability, will continue to dissuade ... Read More
-
Peru Pharmaceuticals & Healthcare Q3 2018
... pharmaceutical sales. The commitment by the Peruvian government toimprove the healthcare systems will increase access to medicine, but with limited resources available to the government, costcontainment measures will pose challenges to innovative drugmakers. However, the ... Read More
-
Slovakia Pharmaceuticals & Healthcare Q3 2018
... an increasing focus on cost containment. While the operating environment isbecoming increasingly aligned with Western European markets, the lack of significant growth opportunities achievable in lessdeveloped emerging European markets will limit the attractiveness for investment. Read More
